摘要
目的了解β2微球蛋白(β2-MG)、癌胚抗原(CEA)、糖类抗原153(CA153)、糖类抗原125(CA125)的临床检测方法,探讨4种血清肿瘤标志物检测对乳腺癌的临床诊断价值。方法选择本院2012年6月至2014年2月门诊收治的30例乳腺癌患者纳入观察组,同时选取同期30例健康体检者纳入对照组,使用免疫比浊法和化学发光法测定两组研究对象血清β2-MG、CA153、CEA、CA125水平,并对其进行统计学分析。结果观察组患者β2-MG、CEA水平及阳性率均明显高于对照组(P<0.05);乳腺癌Ⅲ期患者的CA153水平明显高于Ⅰ期和Ⅱ期患者(P<0.05);患者手术前后β2-MG、CA153和CEA水平相比亦存在显著差异(P<0.05);以β2-MG检测为基准的联合检测与单项检测相比无显著差异(P>0.05),提示联合检测并不能增加乳腺癌临床诊断的特异性。结论虽然4项指标联合检测不能明显提高临床诊断的特异性,但β2-MG、CA153和CEA检测对患者术后随访的意义不能忽视,且CA153检测对患者的预后具有重要的预测价值。
Objective To study the detection of beta 2 microglobulin （β2-MG）, CA153, carcinoembryonic antigen （CEA）, CA125 serum tumor markers in clinic, and to discover the value of four serum tumor markers detection for clinical diagnosis of breast cancer. Method From June 2012 to February 2014, 30 breast cancer outpatient patients were chose in our hospital, and 30 healthy people were chosed as control group, immune turbidimetry and chemiluminescence were used to detect the levels of β2-MG, CA153, CEA and CA125, and the results were analyzed. Result The levels ofβ2-MG and CA125 and the positive rate ofβ2-MG and CA125 in observation group were significantly higher than control group （P 〈 0.05）; CA153 of phase III breast cancer patients were significantly higher than that of patients of stage I and II （P 〈 0.05）; levels of β2-MG, CA153 and CEA of preoperative patients were significant statistical differences to postoperative （P 〈 0,05）; β2-MG detection combined with other detection were no significant statistical difference to only β2-MG detection （P 〉 0.05）, it showed that combine detection did not increase the specificity of clinical diagnosis. Conclusion Although four indicators combined detection could not obviously improve the clinical diagnosis of specific, but the β2-MG, CA153 and CEA detection of patients with postoperative couldn＇t be ignored, and CA153 detection plays an important role in predicting in the prognosis of patients.
出处
《中国医学前沿杂志（电子版）》
2015年第12期44-46,共3页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
